Key result
Activation of RAS components, ACE2 gene polymorphism rs2106809, and use of RAS blockers were not significantly associated with the severity of COVID-19 (p=0.648 for ACEi, p=0.283 for ARBs).
Why the study?
Factors regulating the balance of renin-angiotensin system components, including ACE2 gene polymorphisms and RAS blocker therapy, were suggested to potentially affect the severity of COVID-19.
Does ACE2 gene polymorphism, RAS component levels, or ACEi/ARB therapy affect the severity of COVID-19 in hospitalized patients?
Observational (n=173)
No
Does ACE2 gene polymorphism, RAS component levels, or ACEi/ARB therapy affect the severity of COVID-19 in hospitalized patients?
The severity of COVID-19 correlates with systemic inflammation markers rather than the genetic or functional status of the renin-angiotensin system or the use of ACEi/ARBs.
No link to severity supports continuing RAS blockers; leaves open other polymorphisms or populations.
No takes yet. Share an insight, caveat, or question.
Zuraeva et al. (2023) conducted an observational in COVID-19 (n=173). RAS components, ACE2 gene polymorphism rs2106809, and RAS blockers was evaluated on Severity of COVID-19 course (moderate vs severe). Activation of RAS components, ACE2 gene polymorphism rs2106809, and use of RAS blockers were not significantly associated with the severity of COVID-19 (p=0.648 for ACEi, p=0.283 for ARBs).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: